UniCAR02-T

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameUniCAR02-T
Drug Alias NameUniCAR02-T
ClassificationBiologics
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellex Patient Treatment Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A